Geron initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of Geron with an Outperform rating and $6 price target In myelodysplastic syndromes and myelofibrosis, patients continue to progress on standard of care, which provides plenty of room for the entrance of therapies with novel mechanisms, the analyst tells investors in a research note. The firm says key opinion leader feedback suggests Geron’s Rytelo offers several key points of differentiation in terms of efficacy that will likely make the drug competitive in standard of care.